International Journal of Vascular Medicine

International Journal of Vascular Medicine / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 265670 | 5 pages | https://doi.org/10.1155/2015/265670

Favorable Outcomes after Implantation of Biodegradable Polymer Coated Sirolimus-Eluting Stents in Diabetic Population: Results from INDOLIMUS-G Diabetic Registry

Academic Editor: John A. Kern
Received09 Jul 2015
Revised20 Aug 2015
Accepted20 Aug 2015
Published02 Sep 2015

Abstract

Objective. The main aim is to evaluate safety, efficacy, and clinical performance of the Indolimus (Sahajanand Medical Technologies Pvt. Ltd., Surat, India) sirolimus-eluting stent in high-risk diabetic population with complex lesions. Methods. It was a multicentre, retrospective, non-randomized, single-arm study, which enrolled 372 diabetic patients treated with Indolimus. The primary endpoint of the study was major adverse cardiac events (MACE), which is a composite of cardiac death, target lesion revascularization (TLR), target vessel revascularization (TVR), myocardial infarction (MI), and stent thrombosis (ST). The clinical follow-ups were scheduled at 30 days, 6 months, and 9 months. Results. The mean age of the enrolled patients was 53.4 ± 10.2 years. A total of 437 lesions were intervened successfully with 483 stents (1.1 ± 0.3 per lesion). There were 256 (68.8%) male patients. Hypertension and totally occluded lesions were found in 202 (54.3%) and 45 (10.3%) patients, respectively. The incidence of MACE at 30 days, 6 months and 9 months was 0 (0%), 6 (1.6%), and 8 (2.2%), respectively. The event-free survival at 9-month follow-up by Kaplan Meier method was found to be 97.8%. Conclusion. The use of biodegradable polymer coated sirolimus-eluting stent is associated with favorable outcomes. The results demonstrated in our study depict its safety and efficacy in diabetic population.

1. Introduction

Diabetes mellitus experiences a rampant growth and is currently affecting more than 150 million people worldwide. The onset of diabetes heralds the beginning of the macrovascular complications of our body. Cardiovascular disease accounts for about 80% of the deaths in diabetic populations [1]. The correlation between diabetes and cardiovascular diseases is still nebulous and is presumed to be related to hyperglycemia, hyperinsulinemia, altered lipid metabolism, hypercoagulability, and inflammation [2, 3]. All these propitious changes accelerate atherosclerotic lesion formation causing cardiovascular morbidities. The consequences of cardiovascular intervention in diabetic population are a little less promising. The malefactor behind this is more diffused, deep-rooted, and advanced nature of coronary artery disease in such diabetic individuals [4]. Moreover, the anatomy of coronary arteries involves small vessels and long lesions [5, 6]. The chances of platelet aggregation and thrombotic events are more in diabetics than in nondiabetic individuals [7]. These pose a challenge against treatment with percutaneous coronary intervention (PCI) due to more repetitive restenosis, late luminal loss, and stent thrombosis. But much improvements have been seen in medical management by PCI, if we compare 1-year mortality rates of Bypass Angioplasty Revascularization Investigation (BARI) with Arterial Revascularization Therapy Study (ARTS) [2, 8, 9]. But still there are multiple opinions and dilemmas regarding favorable outcomes of biodegradable polymer coated sirolimus-eluting stents in diabetic population.

Thus, the main aim of our study is to demonstrate safety and efficacy of biodegradable polymer coated sirolimus-eluting stents in diabetic population.

2. Methods

2.1. Study Design and Patient Population

This was a retrospective, single-arm, non-randomized, multicentre registry involving diabetic patients treated with Indolimus sirolimus-eluting stents (Sahajanand Medical Technologies Pvt. Ltd.) from June 2012 to May 2014. The ethical approval was obtained from institutional ethics committee. Written informed consent was obtained from all the patients enrolled in the study or from their legally authorized representative. The study was conducted in accordance with the principle of good clinical practice and Declaration of Helsinki.

2.1.1. Inclusion Criteria

Patients were included if they were at least 18 years of age, had diabetes mellitus according to World Health Organization Report [10], and presented with stable or unstable angina or myocardial ischemia or acute or recent myocardial infarction.

2.1.2. Exclusion Criteria

Patients were excluded (1) if they had known allergy to aspirin, clopidogrel, cobalt-chromium, heparin, ticlopidine, sirolimus, and polymers or (2) if the patient had impaired glucose tolerance without pharmacologic treatment, transient hyperglycemia, or gestational diabetes.

2.2. Stent Description

The Indolimus biodegradable polymer coated sirolimus-eluting coronary stent involves L605 cobalt chromium (Co-Cr) alloy as its stent platform. The biodegradable polymer gives it a strut thickness of 60 μm and drug load of 1.4 μg/mm2. About 70% of drug is released within 7 days and remaining drug is released over a period of 48 days (Figure 1). The drug is released within 7 weeks after the stent implantation from the polymeric layers coated onto the surface of the stent. The biodegradable polymeric film is a blend of different biodegradable polymers, poly L-lactide, 50/50 poly DL lactide-co-glycolide, and polyvinyl pyrrolidone, which undergoes hydrolysis. This process takes approximately 9 to 12 months after which all the polymers degrade naturally and excrete from body in the form of their metabolites.

The average coating thickness of Indolimus stent is between 5 and 6 μm. The Indolimus stent is available in lengths of 8, 12, 16, 20, 24, 28, 32, 36, and 40 mm and available diameters were 2.5, 2.75, 3.0, and 3.5 mm.

2.3. Interventional Procedure and Adjunctive Medications

All patients received a loading dose of 300 mg of aspirin and clopidogrel (300 mg) or prasugrel (60 mg) or ticagrelor (90 gm). The procedural anticoagulation was achieved with either heparin or bivalirudin. However, the intraprocedural administration of glycoprotein IIb/IIIa-inhibitor was at the investigator’s discretion. The procedure was performed according to the standard treatment guidelines of each participating centre. All the patients received dual antiplatelet therapy (aspirin 75–300 mg/daily indefinitely and clopidogrel 75 mg/daily or prasugrel 10 mg/daily or ticagrelor 90 mg twice daily for at least 6 months) after the procedure.

2.4. Study Endpoints

The primary endpoint of the study was a conglomeration of cardiac death, myocardial infarction (MI) (Q-wave and non-Q-wave), target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis (ST). These endpoints were observed at 30-day, 6-month, and 9-month follow-up. The secondary endpoints will be measured at 12 and 24 months and yearly thereafter for five years.

2.5. Definition of Endpoints and Clinical Events

Procedural success was defined in terms of in-hospital MACE. MACE is composed of cardiac death, MI, TLR, or TVR. Death can be cardiac or noncardiac death. Any death due to undetermined cause was reported as cardiac death. Q-wave MI was considered, when there was development of new Q-wave of more than 0.04 seconds in two or more adjoining leads along with increase in cardiac markers like Troponin I or T, creatine kinase, or MB isoform. Non-Q-wave MI was considered when there was more than three-time elevation in creatinine kinase levels along with elevation in MB isoform and Troponin marker T or I without development of new Q-waves. Target lesion revascularization was considered when there was stenosis in treated segment (5 mm proximal and 5 mm distal edges) [11]. Target vessel revascularization was considered when there was stenosis in any segment of the treated vessel. Stent thrombosis (ST) was considered acute when it occurred within 24 hours, subacute when it occurred between 1 and 30 days, and late when it occurred after 30 days. The “definite” stent thrombosis was counted when it was detected angiographically.

2.6. Follow-Up

Clinical follow-up, by hospital appointment or telephonic conversation, was scheduled at 30 days (±7-day window period), 6 months (±15-day window period), and 9 months (±30-day window period). Follow-up data were collected pertaining to current anginal status, intake of antithrombotic regimen, and occurrence of any cardiovascular events or any invasive or noninvasive procedure that the patient had undergone.

3. Results

3.1. Baseline and Lesion Characteristics

A total of 372 diabetic patients with 437 lesions were treated with 483 SES. The average stent length and diameter were mm and mm, respectively. The baseline demographics of all the treated patients are described in Table 1. Out of all the diabetics (mean age = years), majority of them were male (68.8%). The prevalence of hypertension was seen in 202 (54.3%) patients. Double vessel disease was more prevalent and found in 111 (29.8%) patients. Lesions type B, type C and totally occluded lesions were found in 317 (72.5%), 51 (11.7%), and 45 (10.3%) patients, respectively. The detailed angiographic and procedural characteristics are described in Table 2.


CharacteristicsPatients ( patients)

Age (mean ± SD, yrs)53.4 ± 10.2
Male, (%)256 (68.8%)
Hypertension, (%)202 (54.3%)
Dyslipidemia, (%)24 (6.5%)
Family history of CAD, (%)17 (4.6%)
Smoking, (%)67 (18%)
Previous MI, (%)51 (13.7%)
Previous PCI, (%)65 (17.5%)
Previous CABG, (%)17 (4.6%)
Previous stroke, (%)8 (2.2%)

CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, and CABG: coronary artery bypass graft.

CharacteristicsPatients ()
Lesions = 437

Lesion location
Right coronary artery, (%)140 (32.0%)
Left anterior descending, (%)195 (44.6%)
Left circumflex, (%)102 (23.3%)
Left marginal, (%)0 (0.0%)

ACC/AHA lesion classification
Type A, (%)69 (15.8%)
Type B1, (%)167 (38.2%)
Type B2, (%)150 (34.3%)
Type C, (%)51 (11.7%)
Total occlusion, (%)45 (10.3%)

Number of diseased vessels
Single vessel disease, (%)245 (65.9%)
Double vessel disease, (%)111 (29.8%)
Triple vessel disease, (%)16 (4.3%)

Procedural data
Total number of stents, 483
Number of stents per patient (mean ± SD, mm)1.3 ± 0.5
Number of stents per lesion (mean ± SD, mm)1.1 ± 0.3
Average stent diameter (mean ± SD, mm)3.1 ± 0.4
Average stent length (mean ± SD, mm)27.1 ± 8.7

ACC/AHA: American College of Cardiology/American Heart Association.
3.2. Clinical Outcome

The clinical follow-up at 9 months was obtained for 370 (99.4%) patients. At 9-month follow-up, MACE was found to be 2.2% which is a composite of 2 (0.5%) cases of myocardial infarction, 4 (1.1%) cases of target lesion revascularization, and 2 (0.5%) cases of stent thrombosis. The clinical outcomes of patients at 30-day, 6-month, and 9-month follow-up are shown in Table 3. The cumulative event-free survival by Kaplan Meier method was found to be 97.8% at 9-month follow-up (Figure 2).


Clinical outcomes 30-day follow-up6-month follow-up9-month follow-up

Death, (%)0 (0%)0 (0%)0 (0%)
Myocardial infarction, (%)0 (0%)1 (0.3%)2 (0.5%)
 Q-wave, (%)0 (0%)0 (0%)1 (0.3%)
 Non-Q-wave, (%)0 (0%)1 (0.3%)1 (0.3%)
Target lesion revascularization, (%)0 (0%)3 (0.8%)4 (1.1%)
Target vessel revascularization, (%)0 (0%)0 (0%)0 (0%)
Stent thrombosis, (%)0 (0%)2 (0.5%)2 (0.5%)
MACE, (%)0 (0%)6 (1.6%)8 (2.2%)

4. Discussion

Does diabetes mellitus worsens the prognosis and long-term outcomes of patients with coronary artery disease? This long held question still poses a dilemma and the answer quite fluctuates between fact and fiction. It is long established that diabetes increases the rates of restenosis and repeat revascularization after coronary angioplasty [12, 13]. This belief was so severe that in the germinating era of bare metal stents surgery was considered as the primary option for patients with diabetes and multiple-vessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) trial demonstrated the equivalence of angioplasty and bypass surgery but the five-year outcomes of BARI trial demonstrated crystal clear advantage of surgery in subset of patients with diabetes [2].

The introduction of drug eluting stents revolutionized the concept of safety and efficacy in diabetic population. The SIRIUS trial demonstrated that at 9 months TLR rate was reduced in diabetic population from 22.3% in BMS group to 6.9% in SES group [14]. The smaller nonrandomized Porto I trial also demonstrated TLR rates as low as 1.7% [15]. Consistent with this, our study also demonstrated a low TLR rate of only 1.1% at 9-month follow-up. The lower rates of restenosis associated with our stent can be because of lower strut thickness, as stents with lower stent thickness elicit less angiographic and clinical restenosis than stents with thicker struts [16].

Theoretically, due to aggressive atherosclerosis, platelet hyperactivity, impaired fibrinolysis, and endothelial function after arterial injury, diabetes mellitus is associated with antiplatelet resistance and consequent stent thrombosis after angioplasty. This has been proved in previous registry of DES [17]. But, paradoxically, our study presented only two cases of stent thrombosis at 9-month follow-up. This is also supported by the results from ISAR-DIABETES study and DIABETES trial [18, 19].

Elezi et al. reported that one-year event-free survival after stenting is lower in diabetics (73.1%) versus (78.8%) in nondiabetics [12]. The event-free survival at 9 months in our study was found to be 97.8%, which is quite appreciable. Contrastingly, there are studies which demonstrate that cumulative event-free survival is not affected by diabetic status [20].

The results of our study are quite promising. However the long-term follow-up of the study would prove maintained safety and efficacy.

5. Conclusions

The use of Indolimus in high risk diabetic population is associated with lower incidence of TLR, ST, and consequent MACE. Thus, the long held dilemma about the favorable outcomes after implantation of biodegradable polymer coated sirolimus-eluting coronary stent system in diabetic population turns out to be a fact and not fiction.

Conflict of Interests

Dr. Ashok Thakkar and Ms. Shivani Kothari are employees of Sahajanand Medical Technologies Pvt. Ltd. and have provided detailed assistance in literature search and paper preparation. Other authors declare that they have no conflict of interests to disclose concerning the contents of the paper.

References

  1. K. Pyörälä, M. Laakso, and M. Uusitupa, “Diabetes and atherosclerosis: an epidemiologic view,” Diabetes/Metabolism Reviews, vol. 3, no. 2, pp. 463–524, 1987. View at: Publisher Site | Google Scholar
  2. S. B. King, “Surgery is preferred for the diabetic with multivessel disease,” Circulation, vol. 112, no. 10, pp. 1500–1515, 2005. View at: Publisher Site | Google Scholar
  3. M. Roffi and E. J. Topol, “Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes,” European Heart Journal, vol. 25, no. 3, pp. 190–198, 2004. View at: Publisher Site | Google Scholar
  4. T. Y. Goraya, C. L. Leibson, P. J. Palumbo et al., “Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study,” Journal of the American College of Cardiology, vol. 40, no. 5, pp. 946–953, 2002. View at: Publisher Site | Google Scholar
  5. K. E. Kip, D. P. Faxon, K. M. Detre, W. Yeh, S. F. Kelsey, and J. W. Currier, “Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry,” Circulation, vol. 94, no. 8, pp. 1818–1825, 1996. View at: Publisher Site | Google Scholar
  6. M. Mosseri, M. Nahir, Y. Rozenman et al., “Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease,” Cardiology, vol. 89, no. 2, pp. 103–110, 1998. View at: Publisher Site | Google Scholar
  7. P. R. Moreno and V. Fuster, “New aspects in the pathogenesis of diabetic atherothrombosis,” Journal of the American College of Cardiology, vol. 44, no. 12, pp. 2293–2300, 2004. View at: Publisher Site | Google Scholar
  8. A. Abizaid, M. A. Costa, M. Centemero et al., “Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the arterial revascularization therapy study (ARTS) trial,” Circulation, vol. 104, no. 5, pp. 533–538, 2001. View at: Publisher Site | Google Scholar
  9. R. E. Kuntz, “Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma,” Circulation, vol. 99, no. 7, pp. 847–851, 1999. View at: Publisher Site | Google Scholar
  10. World Health Organization, Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation, World Health Organization, Geneva, Switzerland, 2006.
  11. D. E. Cutlip, S. Windecker, R. Mehran et al., “Clinical end points in coronary stent trials: a case for standardized definitions,” Circulation, vol. 115, no. 17, pp. 2344–2351, 2007. View at: Publisher Site | Google Scholar
  12. S. Elezi, A. Kastrati, J. Pache et al., “Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement,” Journal of the American College of Cardiology, vol. 32, no. 7, pp. 1866–1873, 1998. View at: Publisher Site | Google Scholar
  13. J. P. Carrozza, R. E. Kuntz, R. F. Fishman, and D. S. Baim, “Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus,” Annals of Internal Medicine, vol. 118, no. 5, pp. 344–349, 1993. View at: Publisher Site | Google Scholar
  14. I. Moussa, M. B. Leon, D. S. Baim et al., “Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy,” Circulation, vol. 109, no. 19, pp. 2273–2278, 2004. View at: Publisher Site | Google Scholar
  15. R. Seabra-Gomes, “Percutaneous coronary interventions with drug eluting stents for diabetic patients,” Heart, vol. 92, no. 3, pp. 410–419, 2006. View at: Publisher Site | Google Scholar
  16. C. Stettler, S. Allemann, M. Egger, S. Windecker, B. Meier, and P. Diem, “Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials,” Heart, vol. 92, no. 5, pp. 650–657, 2006. View at: Publisher Site | Google Scholar
  17. J. Daemen, P. Wenaweser, K. Tsuchida et al., “Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study,” The Lancet, vol. 369, no. 9562, pp. 667–678, 2007. View at: Publisher Site | Google Scholar
  18. M. Sabaté, P. Jiménez-Quevedo, D. J. Angiolillo et al., “Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial,” Circulation, vol. 112, no. 14, pp. 2175–2183, 2005. View at: Publisher Site | Google Scholar
  19. A. Dibra, A. Kastrati, J. Mehilli et al., “Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients,” The New England Journal of Medicine, vol. 353, no. 7, pp. 663–670, 2005. View at: Publisher Site | Google Scholar
  20. E. Van Belle, C. Bauters, E. Hubert et al., “Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels,” Circulation, vol. 96, no. 5, pp. 1454–1460, 1997. View at: Publisher Site | Google Scholar

Copyright © 2015 Anurag Polavarapu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

764 Views | 297 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.